Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 6;3(5):382-384.
doi: 10.1158/2643-3230.BCD-22-0067.

CAR T-cell Therapy Meets Clonal Hematopoiesis

Ugur Uslu  1 , Carl H June  1   2
Affiliations
Editorial

CAR T-cell Therapy Meets Clonal Hematopoiesis

Ugur Uslu et al. Blood Cancer Discov. .

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al., p. 385 (8).

PubMed Disclaimer

Comment in

  • Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
    Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Saini NY, et al. Blood Cancer Discov. 2022 Sep 6;3(5):385-393. doi: 10.1158/2643-3230.BCD-21-0177. Blood Cancer Discov. 2022. PMID: 35533245 Free PMC article.

Comment on

  • Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
    Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Saini NY, et al. Blood Cancer Discov. 2022 Sep 6;3(5):385-393. doi: 10.1158/2643-3230.BCD-21-0177. Blood Cancer Discov. 2022. PMID: 35533245 Free PMC article.

References

    1. von Bonin M, Jambor HK, Teipel R, Stolzel F, Thiede C, Damm F, et al. Clonal hematopoiesis and its emerging effects on cellular therapies. Leukemia 2021;35:2752–8. - PMC - PubMed
    1. Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 2019;37:375–85. - PubMed
    1. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379:64–73. - PMC - PubMed
    1. Young RM, Engel NW, Uslu U, Wellhausen N, J CH. Next-generation CAR T-cell therapies. Cancer Discov 2022:OF1–OF14. - PMC - PubMed
    1. Teipel R, Kroschinsky F, Kramer M, Kretschmann T, Egger-Heidrich K, Kruger T, et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv 2022;6:1941–6. - PMC - PubMed

MeSH terms